Literature DB >> 15769620

Cyclic nucleotide phosphodiesterase-mediated integration of cGMP and cAMP signaling in cells of the cardiovascular system.

Donald H Maurice1.   

Abstract

Numerous pharmacological and physiological agents acting via either cAMP- or cGMP-mediated impact the activities of cells of the cardiovascular system. While most define cAMP and cGMP signaling systems as separate and independent, recent advances in our understanding of cyclic nucleotide signaling, and more specifically, of the roles which cyclic nucleotide phosphodiesterases (PDEs) play in these events, have altered this view. In this short chapter, I will review the data identifying expression of several PDEs in cells of the cardiovascular system. In addition, I will review the data that identify PDEs as enzymes capable of allowing integration between cAMP and cGMP signaling in cells, and propose that cAMP and cGMP signaling systems can represent parallel and interdependent signaling systems. Moreover, I will propose that cGMP-mediated effects on the activities of variants of the Phosphodiesterase 2 (PDE2), PDE3 and PDE5 families may act to coordinate linkage between cAMP and cGMP signaling in these cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15769620     DOI: 10.2741/1614

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  8 in total

Review 1.  cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.

Authors:  Sharron H Francis; Jennifer L Busch; Jackie D Corbin; David Sibley
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

2.  Therapeutic effects of udenafil on pressure-overload cardiac hypertrophy.

Authors:  Hack-Lyoung Kim; Yong-Jin Kim; Kyung-Hee Kim; Seung-Pyo Lee; Hyung-Kwan Kim; Dae-Won Sohn; Byung-Hee Oh; Young-Bae Park
Journal:  Hypertens Res       Date:  2015-04-02       Impact factor: 3.872

3.  Thrombospondin-1 inhibition of vascular smooth muscle cell responses occurs via modulation of both cAMP and cGMP.

Authors:  Mingyi Yao; David D Roberts; Jeff S Isenberg
Journal:  Pharmacol Res       Date:  2010-10-29       Impact factor: 7.658

Review 4.  Nitric oxide-cyclic GMP signaling in stem cell differentiation.

Authors:  Kalpana Mujoo; Joshua S Krumenacker; Ferid Murad
Journal:  Free Radic Biol Med       Date:  2011-10-06       Impact factor: 7.376

5.  cGMP signals modulate cAMP levels in a compartment-specific manner to regulate catecholamine-dependent signaling in cardiac myocytes.

Authors:  Alessandra Stangherlin; Frank Gesellchen; Anna Zoccarato; Anna Terrin; Laura Ashley Fields; Marco Berrera; Nicoletta Concetta Surdo; Margaret Anne Craig; Godfrey Smith; Graham Hamilton; Manuela Zaccolo
Journal:  Circ Res       Date:  2011-02-17       Impact factor: 17.367

Review 6.  Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics.

Authors:  Emily J Tsai; David A Kass
Journal:  Pharmacol Ther       Date:  2009-03-21       Impact factor: 12.310

7.  cGMP Signaling, Phosphodiesterases and Major Depressive Disorder.

Authors:  Gillian W Reierson; Shuyu Guo; Claudio Mastronardi; Julio Licinio; Ma-Li Wong
Journal:  Curr Neuropharmacol       Date:  2011-12       Impact factor: 7.363

8.  The NO/cGMP pathway inhibits transient cAMP signals through the activation of PDE2 in striatal neurons.

Authors:  Marina Polito; Jeffrey Klarenbeek; Kees Jalink; Danièle Paupardin-Tritsch; Pierre Vincent; Liliana R V Castro
Journal:  Front Cell Neurosci       Date:  2013-11-18       Impact factor: 5.505

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.